News for Sutro Biopharma, Inc. (STRO)

While Donald Trump spared pharma companies from his tariff announcement last week, he revealed yesterday plans to announce tariffs on the industry soon.

**media[580791]**

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 600 points on Friday. The Dow traded up 1.53% to 41,436.27 while t...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 1.5% on Friday. Following the market opening Friday, the Dow traded up 0.31% t...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) ( STRO), a clinical-stage oncology company pionee

**media[556068]**

-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and A

**media[550219]**

SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. ( PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) ( STRO), a clinical-stage oncology company pioneer

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellenceâ„¢ and Sutro Biopharma Inc.today announced that they successf

Sutro Biopharma's valuation remains compelling despite recent market hits, with optimism for a turnaround. Click here to find out STRO stock is a Strong Buy.

Sutro Biopharma stock hits 52-week low at $2.02

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed b

Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 20.27% and 53.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[465481]**